Hormonal
Unimolecular dual-agonists targeting GLP-1 and GIP receptors (e.g., tirzepatide) provide superior glycemic control and weight loss compared to GLP-1 receptor agonists alone by leveraging additive insulinotropic effects and distinct metabolic pathways.
If you have Type 2 Diabetes and struggle with weight, dual-agonist medications (like tirzepatide) may offer better blood sugar control and weight loss than older GLP-1 drugs. These medications work by mimicking gut hormones to boost insulin, reduce appetite, and increase energy expenditure. While they are injections and may cause temporary nausea, the clinical benefits for metabolic health are significant. Consult your doctor to see if this advanced therapy is appropriate for your specific health profile.
Several of these novel molecules have now entered clinical trials and some have demonstrated favorable outcomes when compared with established GLP-1R agonists. For example, tirzepatide (LY3298176), which is a dual GLP-1R-GIPR agonist, showed superior HbA1c lowering efficacy in patients with T2DM versus GLP-1R agonism alone.
Why this rating
The paper is a scoping review citing clinical trials (e.g., tirzepatide outcomes) and extensive preclinical mechanistic data, though it notes that comprehensive understanding of chronic efficacy/safety requires more investigation.
Source
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Franco Folli et al. · American Journal of Physiology-Endocrinology and Metabolism · 2023
DOI 10.1152/ajpendo.00236.2023
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →